Abstract: The present disclosure relates to an injectable lurasidone suspension and a preparation method thereof, and in particular to an irregular form of a lurasidone solid and a pharmaceutical composition thereof. The present disclosure also relates to a preparation method for the solid and the pharmaceutical composition thereof, and an application thereof in the treatment of mental diseases. According to the present disclosure, the lurasidone solid prepared has controllable particle size and has Dv5O particle size of 6 ?m to 110 ?m. The good particle size stability can also he maintained in the pharmaceutical composition. The lurasidone suspension preparation obtained by the method is fast-acting, has a long sustained release period, and can effectively reduce the risk caused by poor patient compliance.

Abstract: In an embodiment, a method includes receiving power signals at respective powered devices of a subsystem. The method further includes coupling, to a power supply with one of the powered devices having a highest priority, one of the power signals received by the one of the powered devices having a highest priority. The method further includes generating a supply signal with the power supply in response to the one of the power signals.

Abstract: In an embodiment, a powered device (PD) interface circuit includes a lower priority PD and a higher priority PD. The lower priority PD is configured to receive, and to couple to a power supply onboard a subsystem, a first power signal from first power source equipment (PSE). And the higher priority PD is configured to receive a second power signal from second PSE, to couple the second power signal to the power supply, and to prevent the lower priority PD from coupling the first power signal to the power supply while the higher priority PD is coupling the second power signal to the power supply. That is, such a PD interface circuit is configured to impart a respective priority to each PD such that if two or more PDs receive power from respective PSEs, then the interface circuit enables only the PD having the higher priority to couple a corresponding PSE power signal to the power supply onboard the subsystem.

Abstract: A computer system processes a message from a user mobile device by receiving the message from the user mobile device, wherein the message comprises a purchase request, and then determining a matching purchase offer in a database containing a plurality of purchase offers, wherein the matching purchase offer corresponds to an offer identified in the purchase request. The system then transmits a purchase request to a purchase agent at a third party provider that is associated with the matching purchase offer, and processing a purchase transaction received from the purchase agent at the third party provider.

Abstract: In an embodiment, a powered device (PD) interface circuit includes a lower priority PD and a higher priority PD. The lower priority PD is configured to receive, and to couple to a power supply onboard a subsystem, a first power signal from first power source equipment (PSE). And the higher priority PD is configured to receive a second power signal from second PSE, to couple the second power signal to the power supply, and to prevent the lower priority PD from coupling the first power signal to the power supply while the higher priority PD is coupling the second power signal to the power supply. That is, such a PD interface circuit is configured to impart a respective priority to each PD such that if two or more PDs receive power from respective PSEs, then the interface circuit enables only the PD having the higher priority to couple a corresponding PSE power signal to the power supply onboard the subsystem.

Abstract: The invention relates to methods and related compositions for enhancing cancer therapy and in particular glutaminase inhibitor therapy. The methods involve methods for identifying patients susceptible to glutaminase inhibitor therapy as well as sensitizing patients to glutaminase inhibitor therapy.

Abstract: Provided herein are methods, compositions, and systems for treating mitochondrial disorders (e.g., MERRF, MELAS, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia, diabetes mellitus and deafness, lactic acidosis, Leber's hereditary optic neuropathy, Wolff-Parkinson-White syndrome, Leigh syndrome, NARP, myoneurogenic gastrointestinal encephalopathy, mitochondrial DNA depletion syndrome) or neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease) by administering aspartate, or an analog or prodrug thereof, or an agent that increases intracellular levels of aspartate. Pharmaceutical compositions and kits for use in treating mitochondrial disorders and neurodegenerative diseases are also described herein. Also provided are methods for treating disease by modulating the redox state of a cell, and methods of treating a proliferative disease by administering a cytosolic aspartate aminotransferase (GOT1) inhibitor.

Abstract: The invention relates to methods and related compositions for enhancing cancer therapy and in particular glutaminase inhibitor therapy. The methods involve methods for identifying patients susceptible to glutaminase inhibitor therapy as well as sensitizing patients to glutaminase inhibitor therapy.

Abstract: Provided herein are methods, compositions, and systems for treating mitochondrial disorders (e.g., MERRF, MELAS, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia, diabetes mellitus and deafness, lactic acidosis, Leber's hereditary optic neuropathy, Wolff-Parkinson-White syndrome, Leigh syndrome, NARP, myoneurogenic gastrointestinal encephalopathy, mitochondrial DNA depletion syndrome) or neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease) by administering aspartate, or an analog or prodrug thereof, or an agent that increases intracellular levels of aspartate. Pharmaceutical compositions and kits for use in treating mitochondrial disorders and neurodegenerative diseases are also described herein. Also provided are methods for treating disease by modulating the redox state of a cell, and methods of treating a proliferative disease by administering a cytosolic aspartate aminotransferase (GOT1) inhibitor.

Abstract: A computer system processes a message from a user mobile device by receiving the message from the user mobile device, wherein the message comprises a purchase request, and then determining a matching purchase offer in a database containing a plurality of purchase offers, wherein the matching purchase offer corresponds to an offer identified in the purchase request. The system then transmits a purchase request to a purchase agent at a third party provider that is associated with the matching purchase offer, and processing a purchase transaction received from the purchase agent at the third party provider.